Immunohistochemistry analysis of AACOCF3 monotherapy and combination treatment with CBP correlated with significant reductions in the levels of tumor cell proliferation markers Ki67, p-cPLA2 and t-cPLA2 (Fig. 5I, K and L). Here, MKI67 is linked to neoplasm.